VU Research Portal
Risk of cardiovascular diseases after Hodgkin lymphoma treatment van Nimwegen, F.A.
2016
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
van Nimwegen, F. A. (2016). Risk of cardiovascular diseases after Hodgkin lymphoma treatment.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
Chapter 5
ƌĂĚŝĂƟŽŶĚŽƐĞͲƌĞƐƉŽŶƐĞƌĞůĂƟŽŶƐŚŝƉĨŽƌƌŝƐŬŽĨŚĞĂƌƚ
ĨĂŝůƵƌĞŝŶƐƵƌǀŝǀŽƌƐŽĨ,ŽĚŐŬŝŶůLJŵƉŚŽŵĂ
^ƵďŵŝƩĞĚ
ϱLJĞĂƌƐĂŌĞƌ,>ĚŝĂŐŶŽƐŝƐ͖ďͿƚŚĞLJǁĞƌĞĚŝĂŐŶŽƐĞĚǁŝƚŚ,>ďĞĨŽƌĞƚŚĞĂŐĞŽĨϱϭLJĞĂƌƐ͖ĐͿ,> ǁĂƐƚŚĞŝƌĮƌƐƚƉƌŝŵĂƌLJ ŵĂůŝŐŶĂŶĐLJ͕ĞdžĐĞƉƚĨŽƌ ŶŽŶͲŵĞůĂŶŽŵĂƐŬŝŶĐĂŶĐĞƌ͕Žƌ ĐĂƌĐŝŶŽŵĂŝŶ ƐŝƚƵŽĨƚŚĞĐĞƌǀŝdžƵƚĞƌŝŽƌƚŚĞďƌĞĂƐƚ͖ĂŶĚĚͿƌĂĚŝŽƚŚĞƌĂƉLJĨŽƌ,>ǁĂƐƚŚĞŽŶůLJƌĂĚŝŽƚŚĞƌĂƉLJ ŐŝǀĞŶƚŽƚŚĞŶĞĐŬŽƌƚƌƵŶŬƉƌŝŽƌƚŽƚŚĞĐƵƚͲŽīĚĂƚĞ͕ǁŚŝĐŚǁĂƐĚĞĮŶĞĚĂƐƚŚĞĚĂƚĞŽĨ,&ĨŽƌ ƚŚĞĐĂƐĞƐ͕ŽƌƚŚĞĚĂƚĞŽĨ,>ĚŝĂŐŶŽƐŝƐƉůƵƐĂƟŵĞŝŶƚĞƌǀĂůĞƋƵĂůƚŽƚŚĞŝŶƚĞƌǀĂůĨƌŽŵƚŚĞĚĂƚĞ ŽĨ,>ĚŝĂŐŶŽƐŝƐƚŽƚŚĞĚĂƚĞŽĨ,&ĚŝĂŐŶŽƐŝƐŽĨƚŚĞĐŽƌƌĞƐƉŽŶĚŝŶŐĐĂƐĞĨŽƌŵĂƚĐŚĞĚĐŽŶƚƌŽůƐ͘
Cases and controls
Ta ble 3: ƐƐŽĐŝĂ Ɵ ŽŶƐďĞ ƚǁ ĞĞŶƚƌ ĞĂ ƚŵĞŶ ƚĂŶĚŚĞĂƌƚĨ ĂŝůƵƌ ĞƌŝƐŬ ηĐ ĂƐĞƐ % ηĐ Ž Ŷ ƚƌ ŽůƐ % dƌ ĞĂ ƚŵĞŶ ƚĨ ĂĐƚ Žƌ (t ot al: 91) (t ot al: 278) RR* 95%CI ptr end ZĂĚŝŽƚŚĞƌ ĂƉ LJ EŽZ dƚ Ž ŵĞĚŝĂƐ ƟŶƵŵŽƌW K 7 7 .7 33 11.9 1 .00 0 .40-2.50 W KͲZ d͕ŶŽŵĞĚŝĂƐ ƟŶĂůZ d 2 2 .2 16 5.8 0 .66 0 .15-2.98 DĞĚŝĂƐ ƟŶĂůZ d͕ŶŽW K ͲZ d 39 42.9 126 45.3 1.87 1.27-2.75 DĞĚŝĂƐ ƟŶĂůZ dΘW K ͲZ d 43 47.2 103 37.0 2.59 1.80-3.72 0.020 Wƌ ĞƐĐƌŝďĞĚŵĞĚŝĂƐ ƟŶĂůĚŽƐĞ Ϭ' LJ;ŶŽŵĞĚŝĂƐ ƟŶĂůZ dͿ 9 11.1 4 9 15.6 1 0.45-2.23 ϮϬͲϯϰ' LJ;ŵĞĚŝĂŶϯϮ' LJͿ 5 6 .2 31 11.7 1 .13 0 .44-2.97 ϯϱͲϯϵ' LJ;ŵĞĚŝĂŶϯϲ' LJͿ 34 42.0 113 42.8 2.10 1.31-3.10 шϰϬ' LJ;ŵĞĚŝĂŶϰϬ' LJͿ 33 40.7 7 1 26.9 2.95 1.87-4.63 0.027
Mean heart dose (E
5
Table 4: DŽĚĞůƐƵŵŵĂƌŝnjŝŶŐŚĞĂƌƚĨ ĂŝůƵƌ Ğƌ Ăƚ ĞƐĂĐĐ Žƌ ĚŝŶŐŵĞĂŶŚĞĂƌƚĚŽƐĞ Ĩƌ Ž ŵƌ ĂĚŝŽƚŚĞƌ ĂƉ LJĂŶĚĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƚƌ ĞĂ ƚŵĞŶ ƚ͘ dƌ ĞĂ ƚĞ ĚǁŝƚŚŽƵƚĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƐ dƌ ĞĂ ƚĞ ĚǁŝƚŚĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƐ ηĐ ĂƐĞƐ ηĐ ŽŶ ƚƌ ŽůƐ RR 95%CI p* ηĐ ĂƐĞƐ ηĐ ŽŶ ƚƌ ŽůƐ RR 95%CI p §Mean heart dose fr
5
Supplemen tal T able 3: ,ĞĂƌƚ ĨĂŝůƵƌ Ğ ƌĂ ƚĞƐ ĞƐ Ɵ ŵĂ ƚĞ Ě ƐĞƉĂƌ Ăƚ ĞůLJ ĨŽƌ Ɖ ĂƟ ĞŶ ƚƐ ǁ ŚŽ Ě ŝĚ ĂŶ Ě ĚŝĚ ŶŽƚ ƌĞ ĐĞŝǀ Ğ ĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƐ͕ ĂĐĐ Ž ƌĚ ŝŶŐ ƚŽ Ě Ğƚ ĂŝůĞĚ ĐĂ ƚĞ ŐŽ ƌŝĞƐ ŽĨŵĞĂŶŚĞĂƌƚĚŽƐĞĨƌ Ž ŵƌ ĂĚŝŽƚŚĞƌ ĂƉ LJ͘ dƌ ĞĂ ƚĞ ĚǁŝƚŚŽƵƚĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƐ dƌ ĞĂ ƚĞ ĚǁŝƚŚĂŶ ƚŚƌ ĂĐLJ ĐůŝŶĞƐ ηĐ ĂƐĞƐ ηĐ ŽŶ ƚƌ ŽůƐ RR 95%CI p* ηĐ ĂƐĞƐ ηĐ ŽŶ ƚƌ ŽůƐ RR 95%CI p §Mean heart dose fr
